anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We recently discovered that microvesicles (MVs)  derived from mesenchymal stem cells (MSCs) overexpressing  miRNA-34a can alleviate experimental kidney injury in mice. In  this study, we further explored the effects of miR34a-MV on renal  fibrosis in the unilateral ureteral obstruction (UUO) models.  Methods. Bone marrow MSCs were modified by lentiviruses  overexpressing miR-34a, and MVs were collected from the  supernatants of MSCs. C57BL6/J mice were divided into control,  unilateral ureteral obstruction (UUO), UUO + MV, UUO + miR-34aMV and UUO + miR-34a-inhibitor-MV groups. MVs were injected  to mice after surgery. The mice were then euthanized on day 7  and 14 of modeling, and renal tissues were collected for further  analyses by Hematoxylin and eosin, Masson's trichrome,  and Immunohistochemical (IHC) staining.  Results. The UUO + MV group exhibited a significantly reduced  degree of renal interstitial fibrosis with inflammatory cell infiltration,  tubular epithelial cell atrophy, and vacuole degeneration compared  with the UUO group. Surprisingly, overexpressing miR-34a enhanced  these effects of MSC-MV on the UUO mice.  Conclusion. Our study demonstrates that miR34a further enhances  the effects of MSC-MV on renal fibrosis in mice through the  regulation of epithelial-to-mesenchymal transition (EMT) and  Notch pathway. miR-34a may be a candidate molecular therapeutic  target for the treatment of renal fibrosis. DOI: 10.52547/ijkd.7673.
Urban Strategies was funded by a Teen Pregnancy Prevention (TPP) grant from the Office of Population Affairs (OPA) within the Department of Health and Human Services (DHHS) to conduct a rigorous evaluation of a TPP program, Project With, to determine the impact of this innovative literary-based curriculum for incarcerated and other justice-involved youth. Project With is a 12-lesson literary-based curriculum, typically delivered in six weekly sessions, with each session having two one-hour long lessons and a meal with facilitators in between the two lessons. Each lesson includes a discussion of selected literary works, including poetry, short stories, and excerpts from films and other videos. The intervention shows potential to promote optimal health and reduce teen pregnancy and sexually transmitted infections (STIs) among incarcerated and other justice-involved youth. This intervention builds upon a former TPP grant. A formative evaluation of the intervention with OPA funding was carried out from 2018-2020. The formative evaluation showed that the curriculum, which explores healthy and unhealthy relationships as they appear within literary works and is facilitated by a caring mentor using a culturally attuned approach, deeply engages incarcerated youth.

This study involves youth aged 15-19 who are incarcerated/justice-involved and who are at high risk for involvement in risky sexual behaviors, including teen pregnancy. The findings from this study are intended to contribute to research on teen pregnancy, sexual health, and healthy relationships. The population of justice-involved/incarcerated youth face historical, structural, and environmental factors that bring about distressing sexual health disparities. Nationwide, 20% of incarcerated youth already have a child or are either pregnant or expecting a child they fathered (Sedlak \& Bruce, 2016). Rates of teen fatherhood for incarcerated youth are seven times higher than their peers, and rates of teen motherhood for incarcerated girls are one-third higher than national averages. Along with disparities related to teen pregnancy, incarcerated youth have high rates of trauma, thus any intervention for these youth must be trauma-informed. A 2010 Office of Juvenile Justice and Delinquency Prevention (OJJDP) report on the needs of incarcerated youth found 70% of all youth had experienced at least one childhood trauma, and 30% had experienced physical abuse, sexual abuse, or both. This study was designed to contribute to our understanding of what works with this population and to strengthen our knowledge base around developing and implementing a sexual health and personal relationships program.

The study will roll out in waves. During each wave a cohort of 8-12 youth from each facility will participate in Project With. After Urban Strategies implements Project With in a given facility, they will wait a period of time (e.g., one week to several months) and will then implement the program with a new cohort of youth. Using this design, each facility will participate in the study multiple times.
PURPOSE: A novel airborn transmissible pathogenic avian influenza virus A/Korean native chicken/Korea/K040110/2010(H9N2) is provided to prevent poultry from low pathogenic avian influenza virus infection. CONSTITUTION: A low pathogenic avian influenza A virus K040110/2010 strain(H9N2)(deposit number KCTC 11938BP) is isolated from domestic poultry. A vaccine for protecting poultry contains the avian influenza virus A and pharmaceutically acceptable carrier or diluents. The vaccine is an attenuated or inactivated type. The vaccine additionally contains an adjuvant and one or more vaccine components for other pathogens. A method for preparing the avian influenza virus A comprises: a step of inoculating the avian influenza virus A to a substrate which is susceptible to the infection; a step of proliferating the avian influenza virus A; and a step of collecting materials containing the avian influenza virus A. [Reference numerals] (AA) Experimental group; (BB) Sampling site by cotton swap; (CC) Virus isolation; (DD) 3 days after inoculation; (EE) 5 days after inoculation; (FF) 7 days after inoculation; (GG) 9 days after inoculation; (HH) 11 days after inoculation; (II) Aggressive inoculation group; (JJ,MM,PP) Oral cavity; (KK,NN,QQ) Cloaca; (LL) Direct spreading group; (OO) Airborne group; (RR) Number of samples confirmed as virus detection positive/number of chickens inoculated by virus
Zika virus (ZIKV), the causative agent of Zika fever, is a flavivirus transmitted by mosquitoes of the Aedes genus. Zika virus infection has become an international concern due to its association with severe neurological complications such as fetal microcephaly. Viral infection can induce the release of ATP in the extracellular environment, activating receptors sensitized by extracellular nucleotides, such as the P2X7 receptor. This receptor is the primary purinergic receptor involved in neuroinflammation, neurodegeneration, and immunity. In this work, we investigated the role of ATP-P2X7 receptor signaling in Zika-related brain abnormalities. Wild-type mice (WT) and P2X7 receptor-deficient (P2X7-/-) C57BL/6 newborn mice were subcutaneously inoculated with 5 × 106plaque-forming units of ZIKV or mock solution. P2X7 receptor expression increased in the brain of Zika virus-infected mice compared to the mock group. Comparative analyses of the hippocampi from WT and P2X7-/-mice revealed that the P2X7 receptor increased hippocampal damage in CA1/CA2 and CA3 regions. Doublecortin expression decreased significantly in the brains of ZIKV-infected mice. WT ZIKV-infected mice showed impaired motor performance compared to P2X7-/- infected mice. WT ZIKV-infected animals showed increased expression of glial markers GFAP (astrocytes) and IBA-1 (microglia) compared to P2X7-/- infected mice. Although the P2X7 receptor contributes to neuronal loss and neuroinflammation, WT mice were more efficient in controlling the viral load in the brain than P2X7 receptor-deficient mice. This result was associated with higher induction of TNF-α, IFN-β, and increased interferon-stimulated gene expression in WT mice than P2X7-/-ZIKV-infected. Finally, we found that the P2X7 receptor contributes to inhibiting the neuroprotective signaling pathway AKT/mTOR while stimulating the caspase-3 activation, possibly two distinct pathways contributing to neurodegeneration. These findings suggest that ATP-P2X7 receptor signaling contributes to the antiviral response in the brain of ZIKV-infected mice while increasing neuronal loss, neuroinflammation, and related brain abnormalities.
In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with CARDENE. The combination is well tolerated. Beta-Blockers:

Cimetidine increases CARDENE plasma levels. Patients receiving the two drugs concomitantly should be carefully monitored. Cimetidine:

Some calcium blockers may increase the concentration of digitalis preparations in the blood. CARDENE usually does not alter the plasma levels of digoxin; however, serum digoxin levels should be evaluated after concomitant therapy with CARDENE is initiated. Digoxin:

Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta-blocker and a calcium channel blocker. Even though such interactions were not seen during clinical studies with CARDENE, an increased volume of circulating fluids might be required if such an interaction were to occur. Fentanyl Anesthesia:

Concomitant administration of nicardipine and cyclosporine results in elevated plasma cyclosporine levels. Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine. Cyclosporine:

When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine or naproxen were added to human plasma (in vitro), the plasma protein binding of CARDENE was not altered.
AIMS: Use of gene expression signatures to predict adjuvant chemotherapy benefit in women with early-stage breast cancer is increasing. However, high cost, limited access, and eligibility for these tests results in the adoption of less precise assessment approaches. This study evaluates the cost impact of PreciseDx Breast (PDxBr), an AI-augmented histopathology platform that assesses the 6-year risk of recurrence in early-stage invasive breast cancer patients to help improve informed use of adjuvant chemotherapy.
MATERIALS AND METHODS: A decision-tree Markov model was developed to compare the costs of treatment guided by standard of care (SOC) risk assessment (i.e. clinical diagnostic workup with or without Oncotype DX) versus PDxBr with SOC in a hypothetical cohort of U.S. women with early-stage invasive breast cancer. A commercial payer perspective compares costs of testing, adjuvant therapy, recurrence, adverse events, surveillance, and end-of-life care.
RESULTS: PDxBr use in prognostic evaluation resulted in savings of $4 million (M) in year one compared to current SOC in 1 M females members. Over 6-years, savings increased to $12.5 M. The per-treated patient costs in year one amounted to $19.5 thousand (K) for SOC and $16.9K for PDxBr.
LIMITATIONS: For simplicity, recurrence was not specified. We performed scenario analyses to account for variations in rates for local, regional, and distant recurrence. Second, a recurrent patient incurs the total cost of treated recurrence in the first year and goes back to remission or death. Third, CDK4/6i treatment is only incorporated in the recurrence costs but not in the first line of treatment for early-stage breast cancer due to limited data.
CONCLUSIONS: Sensitivity analyses demonstrated robust overall savings to changes in all variables in the model. The use of PDxBr to assess breast cancer recurrence risk has the potential to fill gaps in care and reduce costs when gene expression signatures are not available.
The CHoBI7 program is first delivered during group sessions by a health promoter to those residing in a ring around a cholera patient. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A cholera prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After the group session, households receive weekly voice and text messages from the CHoBI7 mHealth program over 12 months on the recommended WASH behaviors.
PROBLEM TO BE SOLVED: To obtain an activator for stimulating immune defense properties which contains a specific polyholoside as an active ingredient and can be used in a cosmetic or medicinal composition. SOLUTION: At least one of polyholeoside containing at least one unit of fucose is used as an active ingredient. As this polyholoside, a heteropolyholoside comprising monosaccharides having different configurations (for example, D- and L isomers) is preferred, particularly α-L-fucose, α-D-galactose or galacturonic acid is preferred. The content of the fucose unit is 10-90wt.%, particularly 15-35wt.% in the polyholoside. This polyholoside is preferably prepared by culturing Klebsiella pneumoniae subsp. Pneumoniae strain BEC1000. The polyholoside is formulated to the composition in an amount of 0.0001-20%, particularly 0.001-10% based on the total weight of the composition.
REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures. In this study, REBUILD will be used in oncology patients undergoing an open, elective, intent-to-cure, laparotomy procedure. The study is a prospective, non-randomized, multi-center study designed to generate descriptive data about the use of REBUILD. The primary safety outcome is reported device-related adverse events. The primary performance outcome is the integrity of the abdominal wall over one year assessed by clinical examination of the abdomen. If available, CT studies performed within 12 months post-procedure will be used to confirm apposition of the medial border of the rectus muscles and integrity of the abdominal wall.
INTRODUCTION: Accurate positioning of components in total knee arthroplasty (TKA) is essential to a satisfactory outcome. Significant malrotation may lead to chronic pain, stiffness, and dysfunction. This study aims to quantify improvements in functional outcomes following revision surgery for malrotation of either one or both components in TKA versus revision for aseptic loosening.
METHODS: This was a retrospective review of TKAs that matched and compared the two-year functional outcomes of the malrotation group to a functionally similar aseptic loosening group. Functional outcomes were compared between groups using Short Form (SF-12), Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and Knee Society Functional Score (KSFS). Student t-tests and chi-squared or Fisher's tests were used for statistical analysis.
RESULTS: Of the patients revised, 24 had malrotation and 57 had aseptic loosening. A total of 16 femoral and 17 tibial components were revised for malrotation. All 16 femoral components were internally malrotated (mean -4.8 ± 4.1 degrees; range, -0.5 to -16.6). Of the tibial components, 15 were internally malrotated, (mean -9.5 ± 6.6 degrees; range, -2.2 to -23.5) and 2 were externally malrotated (mean 4.6 ± 2.1 degrees; range, 3.1 to 6.0). All functional outcome measures significantly improved comparably within both groups preoperatively to 24 months postoperatively. At 24 months, functional outcome measures were comparable between the groups and WOMAC function scores were significantly higher in the malrotation group.
CONCLUSION: Revision TKA for malrotation can yield clinically and statistically significant functional improvements, similar in magnitude to those seen following revision TKA for aseptic loosening.
LEVEL OF EVIDENCE: Level III.
Horseback riding simulator (HRS) will be applied in addition to routine Physiotherapy and Rehabilitation. This group will receive 20 minutes of routine physiotherapy training and 20 minutes of HRS application in addition to 2 sessions per week for 8 weeks.
Chronic pain affects an estimated 11.2% of the US population, costs the United States approximately $635 billion per year in medical expenses and lost productivity, and fuels the current epidemic of opioid addiction. Understanding alternate approaches to chronic pain management is an imperative given new guidelines for the treatment of pain, and preliminary studies indicate that meditation programs may reduce the suffering and distress that accompanies chronic pain. However, much of the research on meditation for pain has examined the effects of scheduled group interventions, delivered in-person by instructors over the course of several weeks. Far less research has looked at the delivery method that is most common and arguably most sustainable for busy adults, namely, smart phone delivered Contemplative Applications (Apps) for Well-being (CAWs). The proposed study will examine the use and impact of a meditation apps in the context of pain. Participants will be randomized to either app or a wait-list group, and will be assessed in terms of self-reported pain, distress, narcotic use. To assess efficacy, the researchers will examine the longitudinal changes in all measures in the mindfulness app group, compared to wait-list control groups.
PCT No. PCT/GB90/01309 Sec. 371 Date Feb. 24, 1992 Sec. 102(e) Date Feb. 24, 1992 PCT Filed Aug. 21, 1990 PCT Pub. No. WO91/02517 PCT Pub. Date Mar. 7, 1991.A process for preparing an oil-in-water emulsion of a drug which is poorly soluble in water wherein the drug (e.g. amphotericin B) is dissolved in a solution of high or low pH prior to the formation of the drug emulsion. The solution of high pH is preferably a 0.5M solution of sodium hydroxide and/or potassium hydroxide and the solution of low pH is preferably a 0.5M solution of hydrochloric acid. The process comprises the steps of (a) dissolving the drug in a solution of high or low pH, (b) adding the resulting solution to a pre-formed emulsion, (c) adding to the emulsion an amount of an acid, base or buffer appropriate to neutralise at least substantially the product of step (b), and (d) where an acid or base is added in step (c), optionally adding sufficient buffer to adjust the pH of the product of step (c) to a desired value. A drug emulsion made by the process is also provided, in which the drug is primarily associated with the oil droplets.
Minimally invasive ultrasound-guided procedures are a mainstay of modern medicine and the number of such procedures continues to grow. Safe, efficient, and precise execution of these procedures requires a clear visualization of the target anatomy and the interventional device (e.g., a needle). While sustained advances in ultrasound technology have led to greatly enhanced visualization of the anatomy and the needle with high image quality, hand-eye coordination of the practitioner continues to be a challenge. In order to properly position the interventional device, the practitioner must alternate their attention between observing the patient, advancing the needle, and viewing the ultrasound image on a separate screen. This study's long-term goal is to develop an advanced visualization platform for ultrasound-guided procedures to overcome this challenge by greatly simplifying hand-eye coordination. The proposed platform will be developed using the latest advances in the augmented reality (AR) technology. Through wearable, see-through AR glasses, the platform will create a virtual display placed in the practitioner's field of view to show live ultrasound images, registered with the transducer and the patient, in the form of a hologram. The investigative team hypothesizes that such visualization will reduce the time of procedure by 20%. This study is aimed providing the practitioner a more intuitive and efficient platform to perform ultrasound-guided procedures and demonstrating improved efficiency through user studies.
<P>PROBLEM TO BE SOLVED: To provide a functional fiber which can suitably be used for body-contacting items such as inner wears, socks, medical care articles, and health-maintaining articles, has a function for protecting the skins to prevent or recover the chapped skins and further a skin ageing-inhibiting function, and to provide a fiber structure containing the functional fibers.  <P>SOLUTION: This functional fiber is characterized by having a collagen proliferation evaluation value of ≥100, preferably containing or attaching 0.01 to 30 wt. % of protein and further preferably containing or attaching 0.01 to 30 wt. % of a phospholipid-like structure. The fiber structure contains at least partially the functional fibers.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The present invention discloses medicine for treating bone diseases, which comprises the following raw materials by part by weight: 5 to 30g of black snake, 0.5 to 9g of horse proter, 1 to 15g of scorpion, 6 to 20g of sappanwood, 5 to 20g of liaogewang, 3 to 25g of gentiana, 3 to 20g of drynaria rhizome and 0.5 to 10g of asarum. The present invention also discloses a method for preparing the medicine. The medicine has all kinds of efficacy of dredging channels, stimulating blood circulation, removing stasis, setting bone, promoting tissue regeneration, removing putridness, generating new tissue, soften hard lumps, dispelling nodes, harmonizing qi and blood, removing inflammation, stopping pain, etc. A patient with bone diseases only needs to apply the medicine and uses the medicine according to the time of a disease course. The effective rate is 100%, and the cure rate is more than 95%. The needed therapeutic time is shorter than the conventional cure time.
Subjects with mild asthma will be treated with omalizumab for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. Omalizumab will be given subcutaneously every 2 to 4 weeks according to the manufacturer's recommendations.
PURPOSE: Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a type of pediatric HLH that occurs frequently in Asia. Although immunochemotherapy based on etoposide and hormone has improved survival rates, there are still about 30% of HLH patients that do not respond. The objective of the article is to examine the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitors for children with relapsed/refractory (r/r) EBV-HLH.
METHODS: A retrospective case note review of four pediatric patients with r/r EBV-HLH who were treated with PD-1 inhibitors at Sun Yat-sen Memorial Hospital, Sun Yat-sen University.
RESULTS: All four patients responded to PD-1 inhibitors and achieved partial response after their first infusion. Plasma EBV DNA copy number and HLH-related monitoring indicators decreased in all of these patients. All patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT), and two were still alive at the last follow-up on December 30, 2022. Two patients died because of transplantation-related complications. Serious side effects included increased liver enzymes and edema in two patients.
CONCLUSION: PD-1 inhibitors are an effective salvage therapy and can provide a bridge to allo-HSCT for pediatric patients with r/r EBV-HLH. However, side effects should be monitered.
Before anesthesia induction, in the ANH Group, blood was withdrawn at a speed of 25-30ml/min from radial artery and stored in standard collection bags. The volume of blood to be removed during ANH was calculated using an established formula as follows: V = EBV (H0 - Ht) / H. During collection, a tilt rocker scale was used to rock, mix, and weigh the blood. To maintain euvolemia, half of the blood volume removed was replaced with 6% hydroxyethyl starch 130/0.4 with medium molecular weight at a 1:1 ratio and half was replaced with crystalloid at a 1:2 ratio. The autologous blood was returned to patients if the intraoperative transfusion trigger (Hb \<8.0g/dl) was reached or at the completion of the operation.